New rules force companies in Japan to address heatstroke crisis
TOKYO - Companies in Japan are now required to take steps to protect their employees against heatstroke, with the government imposing new rules in response to the steadily increasing number of deaths in recent years attributed to the worsening summer heat.
Under a revised ordinance that took effect on June 1, businesses will be penalised if they fail to act after investigations found many deaths resulted from delayed detection of symptoms and inadequate responses.
Companies are required to take measures for staff working for 60 consecutive minutes or for four hours per day in temperatures exceeding 31 deg C, or at 28 deg C or above on the Wet Bulb Globe Temperature – a global heat index calculated based on multiple factors including humidity.
Under the rules, companies must designate a person at each workplace to be responsible for reporting possible heatstroke cases among staff.
Business operators must also set up procedures to prevent the worsening of symptoms, such as having an employee immediately stop working, cooling the person down and ensuring medical support is provided. Employers are required to inform their workforce of the arrangements.
In the event of a breach, penalties include up to six months of imprisonment or a fine of up to 500,000 yen (S$4,352), Japan's Ministry of Health, Labor and Welfare said.
The number of deaths caused by heatstroke at workplaces hit 31 in 2024, exceeding 30 for the third straight year, as Japan logged its equal-hottest summer since comparable data became available in 1898.
Top stories
Swipe. Select. Stay informed.
Singapore Government looking at enhancing laws around vaping to tackle issue of drug-laced vapes in Singapore
Singapore Why the vape scourge in Singapore concerns everyone
Singapore I lost my daughter to Kpod addiction: Father of 19-year-old shares heartbreak and lessons
Singapore Organised crime groups pushing drug-laced vapes in Asia including Singapore: UN
Singapore Govt will continue to support families, including growing group of seniors: PM Wong at PCF Family Day
Singapore From Normal stream to Parliament: 3 Singapore politicians share their journeys
Business 29 Jollibean workers get help from MOM, other agencies, over unpaid salaries
Asia Why China's high-end hotels are setting up food stalls outside their doors
The number of workplace deaths and injuries related to heatstroke in 2024 was a record-high 1,257, the ministry said.
An analysis of 103 heatstroke deaths between 2020 and 2023 found 70 per cent of victims were working outdoors, while 78 cases saw delayed detection of symptoms contributing to the death. In 41 deaths, it was found there was an inadequate response to the worker's symptoms.
Mr Taku Furukawa, a lawyer with expertise in workplace heatstroke compensation cases, stressed companies need to seriously consider the risk posed by the physical intensity of tasks being performed, in addition to monitoring the temperature and time spent working, saying prevention is key. KYODO NEWS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
2 hours ago
- Straits Times
Forum: Subsidised colorectal cancer screening available with family doctors
Find out what's new on ST website and app. We refer to the letters by Mr Ho Kheng Tiong ( End of free test kit distribution can hurt fight against cancer , July 14) and Mr Daniel Yao ( Miscalculation to end distribution of test kits to detect cancer , July 18). The Ministry of Health (MOH) previously worked with the Singapore Cancer Society (SCS) to distribute subsidised faecal immunochemical test (FIT) kits for colorectal cancer screening. It is a good preventive care initiative, but because residents are left on their own to do the test, they may not approach a doctor to discuss eligibility, interpret the results, and obtain advice on the next steps post-screening. Preventive care screening is most effective when paired with the advice and guidance of a family doctor, as part of a long-term patient-doctor relationship. Hence, MOH has shifted to distributing such FIT kits through family doctors to strengthen preventive care and enable better care continuity under Healthier SG. Family doctors can guide individuals along the screening process, from assessing the individual's risk status to explaining the results and promptly arranging for necessary follow-up tests or specialist referrals, if required. SCS remains a strong partner for the ministry to promote cancer prevention and screening. MOH will continue to work with SCS and other community partners to reach out to residents and improve preventive care. MOH strongly encourages eligible Singaporeans to enrol in Healthier SG and go for regular screening. Eligible Healthier SG enrollees can enjoy full subsidies for the FIT kit, screening consultation, and a follow-up consultation, if required. Ruth Lim (Dr) Director, Disease Policy & Strategy Division Ministry of Health
Straits Times
2 hours ago
- Straits Times
Trial of new dengue vaccine begins recruitment for child participants in Singapore
Find out what's new on ST website and app. The study's lead investigator in Singapore, Assistant Professor Chia Po Ying (left), and Dr Zhong Youjia, another investigator on the study. SINGAPORE – A phase three clinical trial is being conducted here to evaluate the safety and efficacy of a new quadrivalent dengue vaccine in children aged two to 17. Developed by US-based pharmaceutical firm MSD, V181 is a single-dose vaccine that aims to provide protection against all four serotypes, or strains, of the dengue virus. Phase three clinical trials are typically the last stage of testing before a drug's details and clinical trial results are submitted to the regulatory authorities for approval. The study's lead investigator in Singapore, Assistant Professor Chia Po Ying, noted that V181 is a live-attenuated vaccine, which uses weakened versions of all four dengue serotypes. 'Using the weakened forms of all these four dengue serotypes stimulates a human immune response to create protection against dengue infection in future,' said Prof Chia, who also heads the National Centre for Infectious Diseases Research Office. The new study here hopes to recruit at least 700 healthy children between the ages of two and 17, including both those who have previously contracted dengue and those who have never had the disease, said Dr Zhong Youjia, another investigator on the study. This particular study focuses on children as they are more vulnerable to dengue and are also at a greater risk of severe infection, said the associate consultant at National University Hospital's (NUH) Khoo Teck Puat – National University Children's Medical Institute. Side effects from the vaccine have been mild and short-lived, said Prof Chia, noting that they include muscle aches and fatigue. Children enrolled in the study will be randomly chosen to get a single shot of either the vaccine or a placebo. 'There have been no serious adverse events linked to vaccination with V181 to date, and the previous trials actually have shown a very good and favourable safety profile,' Prof Chia said. In Singapore, the study is being conducted at NUH and Tan Tock Seng Hospital, which have already started recruiting participants. Only a handful of children have been recruited so far for the study here, which began in June, said Dr Zhong. A third recruitment site, KK Women's and Children's Hospital, is also in the works. As at July 12, there have been 2,816 dengue cases recorded here in 2025, according to figures from the National Environment Agency (NEA). In May, NEA noted that the number of dengue cases recorded here between January and May 2025 has dropped by about 74 per cent from the same period in 2024. Worldwide, the study aims to enrol about 12,000 healthy children, also between the ages of two and 17, who will receive either a single dose of V181 or a placebo. It aims to include more than 30 trial sites in dengue endemic areas in the Asia-Pacific, including Indonesia, Malaysia and the Philippines. Developing effective dengue vaccines has been difficult as the four serotypes are effectively four different viruses, said Prof Chia. While getting infected by one serotype grants lifelong protection against that particular strain, it provides only short-term protection against the other three, she said. This short-term protection eventually wanes, she noted, adding that those who contract dengue more than once risk antibody-dependent enhancement – a phenomenon where antibodies that are generated due to a vaccine or prior infection actually increase the severity of an infection. Dr Zhong noted this can result in dengue shock syndrome, otherwise known as dengue haemorrhagic fever, a potentially life-threatening complication with symptoms including circulatory failure. Designing a dengue vaccine has been challenging as it has to take into account this phenomenon, Prof Chia said. Should the trials be successful and the vaccine meet regulatory requirements, V181 could be commercially available as early as within the next three to five years, said Dr Zhong. Dr Paula Annunziato, senior vice-president for infectious diseases and vaccines global clinical development at MSD Research Laboratories, noted that half the world's population live in areas at risk for dengue. 'If successful, V181 could provide an important single-dose option for at-risk populations, regardless of previous exposure to dengue, to help reduce the significant burden around the globe,' she said. Dengvaxia, developed by Sanofi Pasteur, is currently the only dengue vaccine approved for use in Singapore. However, it is available only for those between 12 and 45 years old who have previously been infected and poses an increased risk of causing severe dengue in those who have never been infected. In May 2024, another quadrivalent vaccine, Qdenga, received pre-qualification from the World Health Organisation (WHO) – a process that aims to ensure the safety and efficacy of treatments – with WHO recommending the vaccine's use for children aged between six and 16 in dengue-prone areas. Developed by Japanese pharmaceutical company Takeda, Qdenga was made available in Malaysia in June 2024 . Qdenga was submitted for approval here in 2022. However, the following year, the Health Sciences Authority said Takeda had withdrawn its application. The authority said then that the company could submit another application with further clinical data on the vaccine meeting the 'required safety, efficacy and quality standards for use locally'.
Straits Times
2 hours ago
- Straits Times
Scalpel, please: Vietnam wants a slice of South-east Asia's medical tourism pie
Find out what's new on ST website and app. - When Mr Cecil Hatfield, 80, decided to seek medical treatment in Vietnam in May for acute hip pain, his British family and friends were 'very sceptical' about his decision. 'They've heard of Singapore, of course, and Malaysia, as well as Thailand. But Vietnam? 'Do they even have good hospitals there?' they asked.'
